Resistance To Anti-HER2 Therapy In Breast Cancer Patients May Be Delayed By Treatment

[News]

Patients with HER2-positive breast cancer being treated with anti-HER2 therapy may be able to prevent or delay resistance to the therapy with the addition of a phosphatidylinositol-3 kinase inhibitor to their treatment regimens...

More... (http://www.medicalnewstoday.com/releases/255365.php)